ReviewInfection & chemotherapy2022
Preliminary Guidelines for the Clinical Evaluation and Management of Long COVID.
Review in Infection & chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 3 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- Clinical practice guideline for long COVID prevention and treatment.The European respiratory journal · 2026Guideline
- Integrated Clinical and Social Impacts of the COVID-19 Pandemic in Korea: A Combined Systematic and Narrative Review.Journal of Korean medical science · 2026Pooled it
- Clinical practice guidelines and expert consensus statements on rehabilitation for patients with COVID-19: a systematic review.BMJ open · 2024Pooled it
- Rehabilitation needs of long COVID patients in British Columbia.PM & R : the journal of injury, function, and rehabilitation · 2026Article
- Gut Microbiota from Patients with Long COVID Persisting for 2 Years Result in Alterations in Mice that Resemble Post-COVID Symptoms.Probiotics and antimicrobial proteins · 2026Article
- Long COVID: a review of mechanisms and treatment modalities.Inflammopharmacology · 2026Review
- Assessment and management of post-COVID-19 pulmonary complications: a rapid review.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Article
- The effects of G1899 Korean red ginseng extract powder on long COVID for acute COVID19 infection: A randomized, double-blind, placebo-controlled trial.Journal of ginseng research · 2025Article
- Understanding and Addressing Long COVID, the Lingering Shadow of COVID-19.Infection & chemotherapy · 2025Article
- Post COVID-19 and Long COVID Symptoms in Otorhinolaryngology-A Narrative Review.Journal of clinical medicine · 2025Review
- Prevalence and risk factors of long COVID-19 persisting for 2 years in Hainan Province: a population-based prospective study.Scientific reports · 2025Article
- A cross-sectional study on the long-term impact of COVID-19: Symptoms, disability and daily functioning.Health SA = SA Gesondheid · 2025Article
- Kyungok-go for fatigue in patients with long COVID: Double-blind, randomized, multicenter, pilot clinical study protocol.PloS one · 2025Article
- COVID-19: a vascular nightmare unfolding.Frontiers in immunology · 2025Review
- [Introduction to the Research Results of Coronavirus Disease 2019 Big Data (K-COV-N) and the Corresponding Utilization Plan].Jugan geon-gang gwa jilbyeong · 2024Article
- Prevalence, Risk Factors, and Impact of Long COVID Among Adults in South Korea.Healthcare (Basel, Switzerland) · 2024Article
- Article
- The Outcome of SARS-CoV-2 Infection in Patients with Lymphoma and the Risk Factors for the Development of Pneumonia.Infection & chemotherapy · 2024Article
- Long Neurocognitive and Neuropsychiatric Sequelae in Participants with Post-COVID-19 Infection: A Longitudinal Study.Neurology international · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long-lasting coronavirus disease 2019 (COVID-19) symptoms beyond 12 weeks, the so-called 'long COVID' have been increasingly reported worldwide. Long COVID can be manifested in various forms, and there is an increasing demand for proper assessment and management. However, it is challenging when trying to determine the best-practice standards of care based on the current evidence because there is no internationally agreed clinical definition or clear treatment pathway. Therefore, the present guidelines have been drafted to provide advice on diagnosis and management based on the latest updated available evidence and the consensus of expert opinion. So far, no standard test and drug treatment can be strongly recommended for patients with long COVID because of a lack of evidence. The present guidelines provide advice based on 12 key questions, including appropriate interventions for long COVID that can be used in clinical practice. Continuous careful observation and studies related to long COVID are needed for the long-term impact of COVID-19 and proper management for long COVID to be determined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.